Evidence map›Paper›PMID 40697524›Full record

ArticleBiochemistry and biophysics reports2025

p62/SQSTM1 impairs immunotherapy in lung adenocarcinoma by suppressing immune infiltration and peripheral immune response.

Haoran Li, Huamin Qin, Qinghan Xin, Jizhuo Gao, Shen Li, Aline M Thomas, Ning Li, Lingzhi Xu, Man Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haoran LiDepartment of Breast Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Huamin QinDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Qinghan XinDepartment of Breast Surgery, Dalian Municipal Central Hospital, Dalian, China.
Jizhuo GaoDepartment of Breast Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Shen LiDepartment of Neurology and Psychiatry, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Aline M ThomasThe Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ning LiDepartment of Foreign Language, Dalian Medical University, Dalian, China.
Lingzhi XuDepartment of Breast Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Man LiDepartment of Breast Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: We aim to find a potential immunotherapeutic target for lung adenocarcinoma (LUAD) patients. Methods: We collected 193 normal and 543 LUAD tumor samples in total from GEO database. ESTIMATE algorithm, limma and ssGSEA methods were used to find immune-related differential expression genes and to quantify the immune infiltration levels. Preclinical experiments were performed to confirm the role of p62 on LUAD cell lines. And retrospective cohort analyses were used to discover the relationship between p62 and LUAD patients' peripheral immune status, tumor immune infiltration levels and prognosis of immunotherapy. Results: We confirmed that p62 was overexpressed in LUAD patients whose expression corresponded with lower survival. Simultaneously, we discovered an association of p62 with immune cells, wherein high p62 expression in LUAD patients corresponded with fewer tumor-infiltrating lymphocytes, again associated with a poorer prognosis. We revealed that p62 significantly promoted cell proliferation, migration, invasion, and epithelial-mesenchymal transition Conclusion: We demonstrated the involvement of p62 in immune cell infiltration and peripheral immune cell status in LUAD, as well as preliminarily characterized its roles in cancer progression, thus identifying a potential prediction and prognostic marker for LUAD immunotherapy.

Indexed as

Circulating lymphocytesImmunotherapyLung adenocarcinomap62/SQSTM1PrognosisTumor microenvironment

Identifiers

PMID40697524
PMCPMC12280890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.